What are the earnings of Lantheus Holdings?
Lantheus Holdings, Inc. (LNTH) delivers strong financial earnings propelled by high market demand for its precision radiopharmaceutical diagnostic and targeted therapeutic products, most notably Pylarify for prostate cancer imaging. In its Q1 financial report, Lantheus posted an adjusted earnings per share (EPS) of $1.46, significantly beating consensus analyst expectations. The company generated strong quarterly revenues exceeding $350 million, supported by healthy gross margins near 67 percent. Solid cash flow from operations, ongoing share repurchase authorizations, and continued investments in next-generation imaging pipelines reinforce its strong financial footing.
Related FAQs
LB Group (a major global producer of titanium dioxide pigments and chemical products) handles sustainability by integrating environmental management, circular economy principles, and green manufacturing practices across its entire industrial opera...
Wall Street analyst consensus price targets for Lantheus Holdings, Inc. (NASDAQ: LNTH) average approximately $125.00, with high-end healthcare projections reaching up to $150.00.
Lantheus is a specialized diagnostic medical imaging company that develops, manufactures, and distributes innovative diagnostic agents and radiopharmaceuticals used globally.
Lantheus Holdings, Inc.
Long-term healthcare and biotechnology investors frequently view Lantheus Holdings as a compelling portfolio asset due to its specialized leadership in precision radiopharmaceuticals and diagnostic imaging products.
Lantheus Holdings, trading under the ticker symbol LNTH, is often evaluated by healthcare and biotechnology sector investors as a compelling long-term growth opportunity driven by leadership in radiopharmaceuticals and diagnostic imaging agents.
Equity research analysts tracking Lantheus Holdings generally issue favorable consensus recommendations leaning heavily toward buy ratings, driven by strong market adoption of its advanced diagnostic imaging agents and radiopharmaceuticals.
Lantheus Holdings anticipates a strong future outlook driven by its leadership in diagnostic imaging and targeted radiopharmaceutical therapeutics, particularly its flagship product Pylarify for prostate cancer imaging.
Lantheus Holdings, Inc.
Equity research analysts covering Teladoc Health, Inc. (TDOC) maintain a cautious consensus rating, predominantly reflecting a neutral or hold posture across Wall Street institutions.
Lantheus Holdings, Inc.
Moody's Corporation (MCO) has demonstrated strong and resilient stock performance recently, trading near upper market valuations supported by robust execution across its core credit rating and financial intelligence divisions.
Lantheus Holdings operates as a commercial-stage life sciences company specializing in diagnostic imaging and radiopharmaceuticals, carrying specific healthcare sector risks.
Lantheus Holdings, Inc. generates an annual revenue of approximately $1.54 billion USD, reflecting stable and high-level financial performance within the specialized diagnostic and targeted radiopharmaceutical healthcare sector.
Larry Fink, the long-serving chief executive officer of BlackRock, maintains a pragmatic and centrist approach to American political engagement, interacting with political leaders across the ideological spectrum while avoiding formal personal endo...
Yes, Louisiana-Pacific Corporation (trading under the ticker LPX) has experienced strong and cyclical market performance, rewarding shareholders significantly during periods of robust housing construction and high demand for oriented strand board ...
Lantheus operates as a specialized commercial-stage life sciences and pharmaceutical enterprise rather than a traditional small-molecule drug maker, focusing extensively on the development, manufacture, and distribution of innovative diagnostic an...
Lantheus Holdings, Inc. (NASDAQ: LNTH) trades at $101.19 per share, backed by a market capitalization of approximately $6.59 billion.